Trials / Completed
CompletedNCT02741739
Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects
A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of REGN1033 Produced From Two Different Cell Lines in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Primary Objective: Determine blood concentrations of two formulations of REGN1033. Secondary Objective: Assess safety and tolerability of REGN1033.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1033 |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-04-01
- Completion
- 2016-05-01
- First posted
- 2016-04-18
- Last updated
- 2016-10-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02741739. Inclusion in this directory is not an endorsement.